EUVIMEDEUVIMED entdecken
Crossref

Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups

Gary E Aspnes, Steven B Coffey, Etzer Darout, Anne-Marie Dechert-Schmitt, Robert G Dullea, Adam S Kamlet, Chris Limberakis, Allyn T Londregan, Kim F McClure, Elnaz Menhaji-Klotz, David W Piotrowski, Jana Polivkova und 6 weitere

Bioorganic & Medicinal Chemistry Letters · 2023-08 · 92 · 129394

DOI: 10.1016/j.bmcl.2023.129394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023-08. Verfasst von Gary E Aspnes und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Amines, Proprotein Convertase 9, Small Molecule Libraries. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our previous work on the optimization of a new class of small molecule PCSK9 mRNA translation inhibitors focused on empirical optimization of the amide tail region of the lead PF-06446846 (1). This work resulted in compound 3 that showed an improved safety profile. We hypothesized that this improvement was related to diminished binding of 3 to non-translating ribosomes and an apparent improvement in transcript selectivity. Herein, we describe our efforts to further optimize this series of inhibitors through modulation of the heterocyclic head group and the amine fragment. Some of the effort was guided by an emerging cryo electron microscopy structure of the binding mode of 1 in the ribosome. These efforts led to the identification of 15 that was deemed suitable for evaluation in a humanized PCSK9 mouse model and a rat toxicology study. Compound 15 demonstrated a dose dependent reduction of plasma PCSK9 levels. The rat toxicological profile was not improved over that of 1, which precluded 15 from further consideration as a clinical candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsAminesProprotein Convertase 9Small Molecule LibrariesAnimalsStructure-Activity RelationshipRatsHumansMiceDose-Response Relationship, DrugMolecular Structure

Stichwörter der Autor:innen

PCSK9Ribosome

Substanzen

PCSK9 InhibitorsAminesProprotein Convertase 9Small Molecule LibrariesPCSK9 protein, human

Autor:innen und Institutionen

  • Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA.
  • Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA. Electronic address: david.w.piotrowski@comcast.net.

Förderung

  • Pfizer

Zitieren

APA

Aspnes, G. E., Coffey, S. B., Darout, E., Dechert-Schmitt, A. M., Dullea, R. G., Kamlet, A. S., Limberakis, C., Londregan, A. T., McClure, K. F., Menhaji-Klotz, E., Piotrowski, D. W., Polivkova, J., Raymer, B., Ruggeri, R. B., Salatto, C. T., Tu, M., Wei, L., & Xiao, J. (2023). Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups. Bioorganic & Medicinal Chemistry Letters, 92, 129394. https://doi.org/10.1016/j.bmcl.2023.129394

Vancouver

Aspnes GE, Coffey SB, Darout E, Dechert-Schmitt AM, Dullea RG, Kamlet AS, et al. Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups. Bioorganic & Medicinal Chemistry Letters. 2023;92:129394. doi:10.1016/j.bmcl.2023.129394

BibTeX
@article{Aspnes2023,
  author = {Aspnes, Gary E and Coffey, Steven B and Darout, Etzer and Dechert-Schmitt, Anne-Marie and Dullea, Robert G and Kamlet, Adam S and Limberakis, Chris and Londregan, Allyn T and McClure, Kim F and Menhaji-Klotz, Elnaz and Piotrowski, David W and Polivkova, Jana and Raymer, Brian and Ruggeri, Roger B and Salatto, Christopher T and Tu, Meihua and Wei, Liuqing and Xiao, Jun},
  title = {Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2023},
  volume = {92},
  pages = {129394},
  doi = {10.1016/j.bmcl.2023.129394}
}
Kostenlos starten →